COMPANY

Ortholevo, Inc.

Ortholevo is a grant-funded therapeutics startup spun out of Boston University and Harvard Medical School (Beth Israel Deaconess Medical Center, Boston, MA), in the preclinical stage of developing locally-acting, injectable treatments for fibrotic diseases. From company website Source · Oct 12, 2026

Keywords:

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $490K (SBIR commercialization 5SB1AR084380-03, continuation, notice Jul 14, 2026). NIH RePORTER 5SB1AR084380-03 (Jul 14, 2026)
Evidence (1 event)
- Jul 14, 2026 · NIH RePORTER 5SB1AR084380-03
  Organization: ORTHOLEVO, INC.; City/State: Lynnfield, MA; Project number: 5SB1AR084380-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 490333; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 14, 2026 Grant Government grant — SBIR: $490,333 (annual award, as published), announced Jul 14, 2026. Agency: NIH/NIAMS. Source: government award database. source ↗
Jul 21, 2025 Grant Government grant — SBIR: $504,601 (annual award, as published), announced Jul 21, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗

Funding

Last 2 years.

Jul 14, 2026 Government grant — SBIR: $490,333 (annual award, as published), announced Jul 14, 2026. Agency: NIH/NIAMS. Source: government award database. source ↗
Jul 21, 2025 Government grant — SBIR: $504,601 (annual award, as published), announced Jul 21, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗